Re-Engineering the Therapeutic Window: Can Pre- Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
1:30 pm - Wednesday 2nd December 2026
- Determining how pre-targeting strategies separate tumour targeting from radionuclide delivery to improve tumour-tobackground ratios and reduce normal tissue exposure
- Examining the biological and translational challenges associated with conventional radiopharmaceutical approaches and where pre-targeting may offer a differentiated path forward
- Sharing lessons learned from candidate selection, platform optimisation and preclinical development when advancing nextgeneration pre-targeting technologies